Precious Metals

[midastouch017]

2 Coronavirus Treatment Stocks to Buy Right Now
Eli Lilly and Kamada are two of the most intriguing companies working on this part of the COVID-19 problem.

George Budwell
(TMFGBudwell)
Sep 9, 2020 at 10:00AM

Kamada: A convalescent plasma therapy play
Kamada is a plasma-centered biopharmaceutical company with two FDA-approved products on the market: Glassia, a treatment for the inherited lung/liver disorder known as alpha-1 antitrypsin deficiency; and Kamrab, a preventative treatment for rabies.

Although neither of its commercial-stage products is a major cash cow, relatively speaking, Kamada has been posting respectable levels of revenue growth, positive free cash flow, and a steadily improving cash position over the past few quarters.

The biotech's main draw for investors, though, arguably isn't its current product line-up, but rather its experimental convalescent plasma therapy for COVID-19. On Aug. 23, President Trump announced that the FDA had issued an emergency use authorization for this intriguing treatment to be administered to hospitalized COVID-19 treatments.

Since then, the scientific community has raised concerns about the effectiveness of convalescent plasma therapy, given the lack of placebo-controlled clinical trials for them. But this skepticism probably won't dim the commercial potential for Kamada's therapy -- at least not in the short term.

The big picture is that this biotech has one of the most advanced plasma-based COVID-19 treatments in development, a fact which might translate into a healthy boost in its sales in the not-so-distant future.

https://finance.yahoo.com/m/ed13f1d6-ee74-33f0-a242-a5492609dfc4/2-coronavirus-treatment.html?source=eptyholnk0000202&utm_source=yahoo-host&utm_medium=feed&utm_campaign=article&yptr=yahoo